Quantification of levetiracetam in human plasma by liquid chromatography–tandem mass spectrometry: Application to therapeutic drug monitoring
- 4 November 2008
- journal article
- Published by Elsevier BV in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 48 (3), 822-828
- https://doi.org/10.1016/j.jpba.2008.05.035
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- A validated chiral LC method for the enantioselective analysis of Levetiracetam and its enantiomer R-α-ethyl-2-oxo-pyrrolidine acetamide on amylose-based stationary phaseJournal of Pharmaceutical and Biomedical Analysis, 2004
- The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetamProceedings of the National Academy of Sciences of the United States of America, 2004
- High‐performance liquid chromatographic determination of Levetiracetam in human plasma: comparison of different sample clean‐up proceduresBiomedical Chromatography, 2003
- Pharmacokinetics and metabolism of 14 C-levetiracetam, a new antiepileptic agent, in healthy volunteersEuropean Journal of Clinical Pharmacology, 2003
- Pyrrolidone derivativesThe Lancet, 2001
- Levetiracetam for partial seizuresNeurology, 2000
- Pharmacokinetic profile of levetiracetam: toward ideal characteristicsPharmacology & Therapeutics, 2000
- A Micromethod for the Determination of the New Antiepileptic Drug Levetiracetam (ucb LO59) in Serum or Plasma by High Performance Liquid ChromatographyTherapeutic Drug Monitoring, 1996
- Clinical pharmacokinetics of new antiepileptic drugsPharmacology & Therapeutics, 1995
- High-performance liquid chromatographic and megabore gas—liquid chromatographic determination of levetiracetam (ucb L059) in human serum after solid-phase extractionJournal of Chromatography B: Biomedical Sciences and Applications, 1994